Progress of immune checkpoint inhibitors in treatment of hematologic malignancies / 白血病·淋巴瘤

ABSTRACT

In recent years, immunotherapy has become an indispensable part in treatment of cancer, and the immune checkpoint inhibitors are the focus of attention. In the 58th American Society of Hematology (ASH) Annual Meeting, the application of immune checkpoint inhibitors in hematologic malignancies had been widely concerned. The recent progress of immune checkpoint inhibitors in hematologic malignancies in this annual meeting will be briefly introduced.